AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00821652
Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod
DrugBank: Resiquimod (DB06530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
Trial: NCT00821652
Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
DrugBank: Resiquimod (DB06530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
Trial: NCT01650194
Drug: enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
Trial: NCT01650194
Drug: abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
Trial: NCT01650194
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
Trial: NCT01775644
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of treatment will be as used in normal daily routine under local labeling.
Trial: NCT01145534
Drug: glibenclamide
RxNorm normalized name: Glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg as pills, taken daily during the morning for 60 days
Trial: NCT00004652
Drug: pimozide
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01361945
Drug: AUY922
RxNorm normalized name: AUY922
DrugBank: AUY922 (DB11881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
Trial: NCT00065260
Drug: r-ATG
RxNorm normalized name: pantolactone, (R)-
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit ATG 3.5mg/kg/day for consecutive 5 days
Trial: NCT00065260
Drug: CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
Trial: NCT00001277
Drug: 68Ga-Dotatate
RxNorm normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
Trial: NCT00001277
Drug: 18F-DOPA
RxNorm normalized name: (-)-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
Trial: NCT00111085
Drug: Clazosentan 1 mg/h
DrugBank: Clazosentan (DB06677)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Trial: NCT02942212
Drug: Nicotine Patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke \>10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
Trial: NCT01647165
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
Trial: NCT01647165
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
Trial: NCT01647165
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
Trial: NCT00572065
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated.
Trial: NCT00572065
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated.
Trial: NCT04259346
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC.
Trial: NCT03715517
Drug: Bupivacaine 0.75% in Dextrose Inj 8.25%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
Trial: NCT03715517
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
Trial: NCT03715517
Drug: Bupivacaine 0.25% Preservative-Free Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% preservative-free injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg⋅kg-¹ bupivacaine 0.25%
Trial: NCT03715517
Drug: Hydromorphone 10 mcg/mL epidural solution
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
Trial: NCT00531284
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
Trial: NCT00531284
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally or by IV infusion prior to carfilzomib
Trial: NCT00291135
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg daily
Trial: NCT03194906
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.
Trial: NCT01946568
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age.
Trial: NCT00111085
Drug: Clazosentan 5 mg/h
DrugBank: Clazosentan (DB06677)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Trial: NCT00111085
Drug: Clazosentan 15 mg/h
DrugBank: Clazosentan (DB06677)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Trial: NCT03201861
Drug: Paclitaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: weekly paclitaxel and cisplatin
Trial: NCT03201861
Drug: EC to docetaxel or paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard adjuvant chemotherapy recommended by guideline
Trial: NCT00593697
Drug: trastuzumab (9 weeks) + docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) (HT x3 -\>FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
Trial: NCT00593697
Drug: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
Trial: NCT01275105
Drug: Brimonidine Tartrate 0.01%
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one drop in each eye at designated visits
Trial: NCT01275105
Drug: Brimonidine Tartrate 0.025%
RxNorm normalized name: BRIMONIDINE TARTRATE 0.025% OPH SOLN
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one drop in each eye at designated visits
Trial: NCT01275105
Drug: Oxymetazoline HCl 0.025%
RxNorm normalized name: OXYMETAZOLINE HCL 0.025% SOLN,NASAL
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one drop in each eye at designated visits
Trial: NCT03281694
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nicotine skin patch (7 mg/24 hrs) and placebo oral solution
Trial: NCT03281694
Drug: AVL-3288
RxNorm normalized name: AVL-3288
DrugBank: AVL-3288 (DB18707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo skin patch and AVL-3288 oral solution (3 mg)
Trial: NCT03281694
Drug: Nicotine + AVL-3288
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
Trial: NCT03286244
Drug: CM082 plus paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles.
Trial: NCT02617199
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
Trial: NCT00614042
Drug: TRU-016 (anti-CD37 protein therapeutic)
RxNorm normalized name: Tru-micin
DrugBank: TRU-015 (DB05580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
Trial: NCT02383563
Drug: metformin extended release
RxNorm normalized name: metFORMIN Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04391101
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400-500ml convalescent plasma
Trial: NCT02136979
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group of patients with propofol-based anesthesia
Trial: NCT02136979
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group of patients with sevoflurane-based anesthesia
Trial: NCT01875250
Drug: Enzalutamide (Xtandi)
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An androgen receptor inhibitor.
Trial: NCT00055302
Drug: Arimidex 1 mg
RxNorm normalized name: Arimidex 1 MG Oral Tablet
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arimidex (anastrozole) 1mg once daily by mouth
Trial: NCT00867867
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9.3 mg once per day, 6 days per week, for 9 months
Trial: NCT00867867
Drug: Ferric pyrophosphate
RxNorm normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate (DB09147)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.3 mg once per day, 6 days per week, for 9 months
Trial: NCT00071253
Drug: Divalproex Sodium (Delayed-Release Tablets)
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00071253
Drug: Divalproex Sodium (Extended-Release Tablets)
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00071253
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00038506
Drug: abacavir/lamivudine/zidovudine
RxNorm normalized name: ABACAVIR/LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00038506
Drug: tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02466516
Drug: SEL
RxNorm normalized name: Selen
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL tablet administered orally once daily
Trial: NCT00726596
Drug: hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
Trial: NCT04024891
Drug: Phentolamine Mesylate Ophthalmic Solution 1%
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Trial: NCT03475524
Drug: MetFORMIN 1000 Mg Oral Tablet
RxNorm normalized name: metFORMIN 1000 mg oral tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral tablet 1ooomg systemic metformin will be given to group
Trial: NCT03475524
Drug: MetFORMIN 500 Mg Oral Tablet
RxNorm normalized name: metFORMIN 500 mg oral tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral tablet 500 mg
Trial: NCT02002052
Drug: Concurrent platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based concurrent chemotherapy in both arms
Trial: NCT00318084
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00319306
Drug: Budesonide/formoterol
RxNorm normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02823509
Drug: Coppertone (BAY 987517)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation-SR15-68_R84-089)
Trial: NCT01208818
Drug: Bortezomib +Dexamethasone regimen
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect.
Trial: NCT02253160
Drug: Granulocyte-colony stimulating factor (G-CSF)
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
Trial: NCT00359463
Drug: eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be administered a single oral dose of 50 mg eltrombopag.
Trial: NCT03710057
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
Trial: NCT00925587
Drug: darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
Trial: NCT01198275
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
Trial: NCT01198275
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
Trial: NCT02155634
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
Trial: NCT00983307
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
Trial: NCT00665665
Drug: NNC 0070-0002-0182
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
Trial: NCT00665665
Drug: NNC 0070-0002-0182
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
Trial: NCT00665665
Drug: NNC 0070-0002-0182
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial